pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
BRISTOL · news · pharmadog
← back to BRISTOL
News mentioning BRISTOL
109
stories
Jun 16, 26
Edgewise heart drug passes key trial test
biopharma dive
Jun 16, 26
Neumora depression drug fails; EnGene to cut 50% of staff
biopharma dive
Jun 15, 26
Medicare drug price rule may target under-the-skin Keytruda and Opdivo
biopharma dive
Jun 11, 26
STAT+: ‘Synthetic lethality’ could trigger another round of biotech M&A
stat
Jun 11, 26
Takeda's plaque psoriasis pill beats Bristol Myers' Sotyktu in Phase 3
endpoints
Jun 11, 26
Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
biopharma dive
Jun 8, 26
Tango data add to growing momentum for pancreatic cancer drugs
biopharma dive
Jun 8, 26
Incyte to buy blood disorder drug in possibly $2B deal
biopharma dive
Jun 5, 26
Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?
biopharma dive
Jun 4, 26
Alnylam, Inceptive ink AI deal potentially worth $2B
biopharma dive
Jun 3, 26
Bristol Myers turns focus to AI costs after broad rollout to workers
endpoints
Jun 3, 26
House bill aims to crack down on China biotech deals
biopharma dive
May 31, 26
STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
stat
May 29, 26
STAT+: At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer
stat
May 29, 26
Bristol Myers unveils data for one of its next-gen blood cancer drugs
biopharma dive
May 29, 26
Replimune takes third swing at cancer drug approval following ‘productive’ FDA talks
biopharma dive
May 29, 26
#ASCO26: Bristol Myers details Phase 3 trial win for Pomalyst successor
endpoints
May 29, 26
Pfizer, Innovent strike $10B cancer drug deal
biopharma dive
May 19, 26
STAT+: Pharmalittle: We’re reading about a Supreme Court setback for pharma, TrumpRx expands and much more
stat
May 18, 26
STAT+: Supreme Court rejects challenge to Medicare drug price negotiation
stat
May 18, 26
Regeneron immunotherapy combo comes up short in melanoma trial
biopharma dive
May 15, 26
STAT+: Pharmalittle: We’re reading about U.S. pressuring Germany on drug prices, FDA upheaval and biotech clinical trials, and more
stat
May 14, 26
Biogen pushing tau drug forward despite Alzheimer’s study failure
biopharma dive
May 14, 26
STAT+: Pharmalittle: We’re reading about upbeat results for a Duchenne drug, Takeda layoffs, and much more
stat
May 13, 26
STAT+: Pharmalittle: We’re reading about FDA’s Makary resigning, a Lilly weight loss drug trial, and more
stat
May 12, 26
STAT+: European Union inks a draft deal to boost local production of medicines and avoid shortages
stat
May 12, 26
STAT+: Hims’ sales miss as telehealth competition grows
stat
May 12, 26
STAT+: Pharmalittle: We’re reading about pharma lobbying, Bristol’s deal with a Chinese partner, and more
stat
May 12, 26
Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion
biopharma dive
May 12, 26
A year after Vertex’s big launch, pain drug research faces a pivotal moment
biopharma dive
← prev
page 3 of 4
next →
